跳至主要内容
临床试验/NCT04186546
NCT04186546进行中(未招募)不适用

Zephyr Valve Registry

Pulmonx Corporation11 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2019年11月25日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
150
试验地点
11
主要终点
Incidence Rate of Pneumothorax from Baseline to 45-days post-procedure

研究概览

简要总结

The purpose of this Post-Approval Registry is to gather ongoing safety and effectiveness assessment of the Zephyr Valve treatment in a real-world setting.

详细描述

The Zephyr Valve Registry (ZEVR) is a multi-center, single-arm, prospective Registry. The objective of this Registry is to provide ongoing safety and effectiveness assessment of the Zephyr Valve treatment of patients with hyperinflation associated with severe emphysema, in regions of the lung that have little to no collateral ventilation.

Approximately 150 patients undergoing Zephyr Valve treatment in the commercial setting will be enrolled and followed out to 3 years. Assessments will be conducted at 45-days, 6-months, 12-months, 24-months and 36-months post-procedure. The Zephyr Valve Registry will be conducted at a minimum of 5, and a maximum of 10 clinical sites.

Subjects prescribed Zephyr Valve treatment for their emphysema will be consented and will be enrolled only after determination of little to no collateral ventilation between target and ipsilateral lobes. Safety and effectiveness of the Zephyr Valve treatment will be evaluated post-treatment based on data collected out to 3 years after the treatment.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Subjects with severe emphysema considered appropriate for the procedure by the physician.
  • Subjects who signed an Informed Consent Form to allow data collection.

排除标准

  • Subjects determined to have collateral ventilation between the target(s) and ipsilateral lobe(s).

结局指标

主要结局

Incidence Rate of Pneumothorax from Baseline to 45-days post-procedure

时间窗: Baseline to 45-days post-procedure

The percentage of study participants undergoing the Zephyr Valve Procedure who develop a pneumothorax from the date of the procedure to 45-day post intervention.

Incidence Rate of Serious Adverse Events (SAEs) of Interest from Baseline to 3 years post-procedure

时间窗: Baseline to 3 years post-procedure

The percentage of study participants who experience a device and/or procedure related SAE including but not limited chronic obstructive pulmonary disease (COPD) exacerbation, hemoptysis, pneumonia, respiratory failure, Valve expectoration and Valve migration

次要结局

  • Percent Change in Forced Expiratory Volume in 1 second FEV1 (L) Post Bronchodilator from baseline to 6-months, 12-months, 24-months and 36-months post-procedure(At baseline, 6-months, 12-months, 24-months and 36-months post-procedure)
  • Absolute Change in Six-Minute Walk Distance (6MWD) from baseline to 6-months and 12-months post-procedure(At baseline, 6-months and 12-months)
  • Absolute Change in Treated Lobar Volume Reduction (TLVR) after 45-days post-procedure(At baseline and after 45-days post-procedure)
  • Absolute Change in Forced Expiratory Volume in 1 second FEV1 (L) Post Bronchodilator from baseline to 6-months, 12-months, 24-months and 36-months post-procedure(At baseline, 6-months, 12-months, 24-months and 36-months post-procedure)
  • Percent Change in Forced Expiratory Volume in 1 second FEV1 (% Predicted) Post Bronchodilator from baseline to 6-months, 12-months, 24-months and 36-months post-procedure(At baseline, 6-months, 12-months, 24-months and 36-months post-procedure)
  • Percent Change in Treated Lobar Volume Reduction (TLVR) after 45-days post-procedure(At baseline and after 45-days post-procedure)
  • Absolute Change in Forced Expiratory Volume in 1 second FEV1 (% Predicted) Post Bronchodilator from baseline to 6-months, 12-months, 24-months and 36-months post-procedure(At baseline, 6-months, 12-months, 24-months and 36-months post-procedure)
  • Absolute Change in St. George's Respiratory Questionnaire (SGRQ) Total Score from baseline to 6-months and 12-months post-procedure(At baseline, 6-months and 12-months)
  • Absolute Change in BODE Index Total Score from baseline to 6-months and 12-months post-procedure(At baseline, 6-months and 12-months)
  • Percent Change in Six-Minute Walk Distance (6MWD) from baseline to 6-months and 12-months post-procedure(At baseline, 6-months and 12-months)
  • Percent Change in St. George's Respiratory Questionnaire (SGRQ) Total Score from baseline to 6-months and 12-months post-procedure(At baseline, 6-months and 12-months)
  • Percent change in BODE Index Total Score from baseline to 6-months and 12-months post-procedure(At baseline, 6-months and 12-months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验

Zephyr Valve Registry (ZEVR) | 临床试验